Dronabinol as an Adjunct for Reducing Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Low Back PainChronic PainBack Injuries
Interventions
DRUG

Dronabinol

Eligible subjects will be randomized (2:1) to dronabinol or placebo, administered orally. The dose of dronabinol will be titrated such that on Day 1, subjects will take 2.5 mg, twice. On subsequent days patients may gradually increase the total number of doses, by one dose each day, as needed and tolerated until either the optimal dose is achieved, or the dose reaches 30 mg THC per day.

DRUG

Placebo

Matching placebo will be prepared and administered in the same manner as the active medication. Titration will occur in a masked fashion such that individuals assigned to placebo undergo a similar perceived titration process.

Trial Locations (1)

77030

RECRUITING

Michael E Debakey VA Medical Center, Houston

All Listed Sponsors
lead

Christopher D. Verrico

OTHER